Arctic Bioscience (ABS) investor relations material

Executive summary

• Achieved 35.2% year-over-year Nutra revenue growth in H1 2026, with NOK 23.3m versus NOK 17.2m in H1 2025; US market revenue up 87% and now the largest segment.

• Robust order pipeline and recurring customers underpin continued growth, with delayed H1 shipments completed early Q3.

• Secured NOK 15m long-term loan, strengthening liquidity and supporting ongoing operations.

• Advanced HR0350 psoriasis drug candidate with positive phase IIb data, ongoing phase III planning, and peer-reviewed publications.

• Improved adjusted EBITDA to NOK -12.1m from NOK -13.6m year-over-year, reflecting cost control and operational efficiencies.

Financial highlights

• Total revenue for H1 2026 reached NOK 25.0m, with sales revenue at NOK 23.3m, up 35.2% year-over-year.

• Gross margin for H1 2026 was 29.8%, down from 33.4% in H1 2025.

• EBITDA and adjusted EBITDA both at NOK -12.1m, reflecting ongoing investment in pharma development.

• Net loss for H1 2026 was NOK -18.0m, a slight improvement from NOK -18.9m in H1 2025.

• Available liquidity at period end was NOK 1.2m, supported by new long-term funding; equity ratio at 54%.

Outlook and guidance

• Positive growth outlook for Nutra, with US and APAC regions prioritized for expansion.

• China partnership signals further H2 2026 growth; robust order pipeline and recurring customers expected to drive results.

• Pharma development to be financed separately; focus on advancing HR0350 to Phase III and securing partnerships.

• Additional HR0350 clinical data to be published in H2 2026; ongoing evaluation of further financing initiatives.

• Near-term priorities include delivering H2 orders, protecting margins, and maintaining liquidity discipline.